Gilead Sciences (GILD) Enterprise Value (2009 - 2026)

Gilead Sciences has reported Enterprise Value for 18 years, with the latest figure at -$7.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 3.53% year-over-year to -$7.7 billion; the trailing twelve-month figure through Mar 2026 stood at -$7.7 billion (up 3.53% YoY), and the FY2025 full-year result was -$7.7 billion, up 23.41% from the prior year.
• Enterprise Value for Q1 2026 stood at -$7.7 billion, roughly flat from -$7.7 billion in the prior quarter.
• The five-year high for Enterprise Value was -$2.9 billion in Q2 2024, with the low at -$10.1 billion in Q4 2024.
• Historically, Enterprise Value has averaged -$6.4 billion across 5 years, with a median of -$6.4 billion in 2022.
• Annual changes were most pronounced in 2024 — Enterprise Value surged 57.57% — and 2025, when it tumbled 85.47%.
• Gilead Sciences' Enterprise Value stood at -$6.4 billion in 2022, then fell by 14.53% to -$7.3 billion in 2023, then slumped by 37.11% to -$10.1 billion in 2024, then grew by 23.41% to -$7.7 billion in 2025, then slipped by 0.14% to -$7.7 billion in 2026.
• The last three Enterprise Value figures came in at -$7.7 billion (Q1 2026), -$7.7 billion (Q4 2025), and -$7.4 billion (Q3 2025), per Business Quant data.